Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Indexes  >  Nasdaq  >  NASDAQ Comp.    COMP   XC0009694271


SummaryMost relevantAll NewsNews of the index componentsMarketScreener Strategies

GoodRx shares jump 40% in Nasdaq debut after $1 billion IPO

share with twitter share with LinkedIn share with facebook
09/23/2020 | 05:37pm EDT

Shares of private-equity-backed GoodRx Holdings Inc surged 40% in their debut on the Nasdaq on Wednesday after the online prescription drug platform raised $1.14 billion (£895.9 million) in its initial public offering.

The stock opened at $46, compared with the IPO price of $33 per share, which was above its targeted range. At the opening price, GoodRx is valued at nearly $18 billion, more than six times the valuation it commanded during its last private fundraise in 2018.

GoodRx's shares hit a session high of $49.57, a jump of over 50%.

The California-based company gathers information for more than 70,000 U.S. pharmacies to track drug prices and offers discount coupons. It makes money by charging fees to partnering pharmacy benefits managers.

"We just think now is really a fantastic time to raise our profile, sure, but more importantly to be able to offer these services to people at a time when they need it," Doug Hirsch, GoodRx's co-chief executive and co-founder, said in an interview.

GoodRx's debut comes on the heels of the successful IPOs of data warehouse company Snowflake Inc and Unity Software Inc, underscoring investor appetite for new stocks which promise rapid revenue growth.

Moreover, shelter-in-place restrictions to control the pandemic have prompted people to turn to virtual consultations and online purchases of medicines, benefiting companies like GoodRx, which is among the few startups to be profitable at the time of its IPO.

"Healthcare companies have been the most active segment of the IPO market this year," said Kathleen Smith of IPO research firm Renaissance Capital. "Investors had a strong interest in GoodRx due to its 50%+ revenue growth and superior 40%+ EBITDA margins."

GoodRx posted $257 million in revenue for the first six months of 2020, up from $173 million a year earlier. Net income totaled $55 million, compared with $31 million last year.

By Niket Nishant

share with twitter share with LinkedIn share with facebook
All news about NASDAQ COMP.
02:31aANALYSIS : After America First, some investors bet on a Biden boost abroad
02:31aBulls are back in the Nasdaq and options are aflutter
02:30aJACK MA : Stock market boom, new listings mint China billionaires at record pace
01:59aDidi considers 2021 IPO in Hong Kong, targets more than $60 billion valuation..
01:56aAsian stocks dip as U.S. political concerns grow
01:53aDidi considers 2021 IPO in Hong Kong, targets more than $60 bln valuation, so..
12:45aWall Street slips as stimulus uncertainty drags on
10/19REFILE-GLOBAL MARKETS-Asian stocks dip as U.S. political concerns grow
10/19Euronext plagued by two glitches Monday, latest exchange to go down
10/19FACTBOX : From hungry squirrels to cyberattacks, exchange outages roil markets
More news
Duration : Period :
NASDAQ Comp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NASDAQ COMP.
Short TermMid-TermLong Term
Heatmap :